Universal Biosensors, Inc. (ASX:UBIO)

Market Cap	18.48M
Revenue (ttm)	6.28M
Net Income (ttm)	-14.24M
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,000
Average Volume	119,823
Open	0.0400
Previous Close	0.0400
Day's Range	0.0400 - 0.0400
52-Week Range	0.0340 - 0.0440
Beta	n/a
RSI	58.68
Earnings Date	Apr 28, 2025

About Universal Biosensors

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO₂, malic acid, glucose, fructose, total acid, and titratable acid...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 76
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: UBIO

Financial Performance

In 2024, Universal Biosensors's revenue was 6.28 million, a decrease of -5.28% compared to the previous year's 6.63 million. Losses were -14.24 million, 111.2% more than in 2023.